Fluocinolone Acetonide Implant Retisert

Jaffe GJ, Martin D, CaUanan D, et al. Fluocinolone acetonide implant (Retisert) for noninfectious posterior uveitis. Fluocinolone acetonide implant (Resisert) for noninfectious posterior uveitus. Fluocinolone Acetonide Uveitis Smdy Group. Ophthalmology 2006 113 1020. [Pg.314]

Driot JY, Novack G, Rittenhouse K, Milazzo C, Pearson PA. Ocular pharmacokinetics of fluocinolone acetonide after Retisert intravitreal implantation in rabbits over a 1-year period. J Ocul Pharmacol Ther 2004 20(3) 269-270. [Pg.300]

Retisert Fluocinolone acetonide Bausch Lomb Marketed product Uveitis Intravitreal implant... [Pg.35]

Intravitreal triamcinolone has been used to treat diffuse diabetic macular edema. Also, an intravitreal implant delivering fluocinolone acetonide (Retisert) is effective in the treatment of patients with noninfectious posterior uveitis who have failed to respond to conventional treatment. [Pg.50]

Another relatively recent development for the management of intermediate and/or posterior uveitis is the sustained-release intravitreal corticosteroid implant, for example, Retisert (fluocinolone acetonide 0.59 mg Bausch Lomb, Rochester, NY, USA). Retisert is indicated fc)r the treatment of chronic noninfectious uveitis affecting the posterior segment of the eye. An intravitreal dexamethasone implant is also currently luider investigation. [Pg.594]

Big Chemical Encyclopedia